摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(benzyloxy)-5-methyl-4-oxo-N-(tetrahydrofuran-2-ylmethyl)-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide | 1186239-13-3

中文名称
——
中文别名
——
英文名称
3-(benzyloxy)-5-methyl-4-oxo-N-(tetrahydrofuran-2-ylmethyl)-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide
英文别名
5-methyl-4-oxo-N-(oxolan-2-ylmethyl)-3-phenylmethoxythieno[3,2-c]quinoline-2-carboxamide
3-(benzyloxy)-5-methyl-4-oxo-N-(tetrahydrofuran-2-ylmethyl)-4,5-dihydrothieno[3,2-c]quinoline-2-carboxamide化学式
CAS
1186239-13-3
化学式
C25H24N2O4S
mdl
——
分子量
448.543
InChiKey
RHWOJPAHWQBGQI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    32
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    96.1
  • 氢给体数:
    1
  • 氢受体数:
    5

文献信息

  • FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
    申请人:FUJII Nobuhiro
    公开号:US20090227561A1
    公开(公告)日:2009-09-10
    The present invention provides a compound having a superior Smo inhibitory activity and lower toxicity, which is sufficiently satisfactory as a pharmaceutical product. The present invention provides a compound represented by the formula wherein ring A is 5- to 7-membered ring optionally having substituent(s), where substituents are optionally bonded to each other to form a ring; X is O, S or NR 1 (R 1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s)); R 2 is carbamoyl optionally having substituent(s); and R 3 is hydroxy optionally having substituent(s), or a salt thereof.
    本发明提供了一种具有优异的Smo抑制活性和较低毒性的化合物,该化合物作为药物产品是完全令人满意的。本发明提供了一种由下式表示的化合物: 其中,环A是5-至7-成员环,可选择地具有取代基,其中取代基可选择地与彼此结合形成环;X是O、S或NR1(R1是原子或具有取代基的基团);R2是基甲酰,可选择地具有取代基;R3是羟基,可选择地具有取代基,或其盐。
  • US8217176B2
    申请人:——
    公开号:US8217176B2
    公开(公告)日:2012-07-10
  • US8399449B2
    申请人:——
    公开号:US8399449B2
    公开(公告)日:2013-03-19
  • [EN] FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ HÉTÉROCYCLIQUE FUSIONNÉ ET SON UTILISATION
    申请人:TAKEDA PHARMACEUTICAL
    公开号:WO2009107850A2
    公开(公告)日:2009-09-03
    The present invention provides a compound having a superior Smo inhibitory activity and lower toxicity, which is sufficiently satisfactory as a pharmaceutical product.The present invention provides a compound represented by the formula (I) wherein ring A is 5- to 7-membered ring optionally having substituent(s), where substituents are optionally bonded to each other to form a ring; X is O, S or NR1 (R1 is a hydrogen atom or a hydrocarbon group optionally having substituent(s)); R2 is carbamoyl optionally having substituent(s); and R3 is hydroxy optionally having substituent(s), or a salt thereof.
查看更多